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Serum Proteomic Profiling to 
Identify Biomarkers of Premature 
Carotid Atherosclerosis
Santosh D. Bhosale1, Robert Moulder  1, Mikko S. Venäläinen  1, Juhani S. Koskinen  2,6, 
Niina Pitkänen6, Markus T. Juonala2, Mika A. P. Kähönen3, Terho J. Lehtimäki4, Jorma  
S. A. Viikari2, Laura L. Elo1, David R. Goodlett1,5, Riitta Lahesmaa1 & Olli T. Raitakari6,7
To evaluate the presence of serum protein biomarkers associated with the early phases of formation 
of carotid atherosclerotic plaques, label-free quantitative proteomics analyses were made for serum 
samples collected as part of The Cardiovascular Risk in Young Finns Study. Samples from subjects who 
had an asymptomatic carotid artery plaque detected by ultrasound examination (N = 43, Age = 30–45 
years) were compared with plaque free controls (N = 43) (matched for age, sex, body weight and 
systolic blood pressure). Seven proteins (p < 0.05) that have been previously linked with atherosclerotic 
phenotypes were differentially abundant. Fibulin 1 proteoform C (FBLN1C), Beta-ala-his-dipeptidase 
(CNDP1), Cadherin-13 (CDH13), Gelsolin (GSN) and 72 kDa type IV collagenase (MMP2) were less 
abundant in cases, whereas Apolipoproteins C-III (APOC3) and apolipoprotein E (APOE) were more 
abundant. Using machine learning analysis, a biomarker panel of FBLN1C, APOE and CDH13 was 
identified, which classified cases from controls with an area under receiver-operating characteristic 
curve (AUROC) value of 0.79. Furthermore, using selected reaction monitoring mass spectrometry 
(SRM-MS) the decreased abundance of FBLN1C was verified. In relation to previous associations of 
FBLN1C with atherosclerotic lesions, the observation could reflect its involvement in the initiation of 
the plaque formation, or represent a particular risk phenotype.
Atherosclerotic cardiovascular diseases are amongst the leading causes of death globally1. Atherosclerosis is char-
acterized by the accumulation of pro-atherogenic lipoprotein particles in the sub-endothelial space of large- and 
medium-sized arteries2. The process is initiated by the trapping of apolipoprotein B particles in arterial intima by 
proteoglycans, followed by subsequent modifications, such as aggregation and oxidation, leading to the develop-
ment of atherosclerotic plaques3. The rupture of a critically located atherosclerotic plaques can result in myocar-
dial infarction and stroke4.
Ultrasound examination can be used to identify thickening of the intima-media in the carotid arteries and is 
used to detect and monitor both subclinical and clinical atherosclerosis5. Although it is unclear how the diffuse 
thickening of carotid artery wall represents the subclinical phase, there is a consensus that local carotid plaques, 
defined as distinct protrusions from the carotid vessel wall into the lumen, are indicative of specific phenotypic 
changes associated with an active atherosclerotic process6. As there is compelling evidence that the atheroscle-
rotic process often starts early in life and may remain asymptomatic for several decades7, the study of young 
and middle-aged adults with non-obstructive carotid plaques provides an opportunity to explore biomarkers 
for early-stage preclinical atherosclerosis. Such markers may have potential in diagnostics and in understand-
ing the disease etiology. Since atherosclerosis is a circulatory manifestation, the extracellular proteome, which 
includes proteins like collagens, elastin, proteoglycans, lipoproteins and glycoproteins, is an important analytical 
1Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland. 2Department of 
Medicine, University of Turku and Division of Medicine, Turku University Hospital, Turku, Finland. 3Department of 
Clinical Physiology, Tampere University Hospital and University of Tampere, Faculty of Medicine, Tampere, Finland. 
4Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center-Tampere, 
Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland. 5Department of Pharmaceutical 
Science, University of Maryland, Baltimore, Maryland, USA. 6Research Centre of Applied and Preventive 
Cardiovascular Medicine, University of Turku, Turku, Finland. 7Department of Clinical Physiology and Nuclear 
Medicine, Turku University Hospital, Turku, Finland. Correspondence and requests for materials should be addressed 
to R.L. (email: rilahes@utu.fi) or O.T.R. (email: olli.raitakari@utu.fi)
Received: 16 February 2018
Accepted: 31 May 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCieNTiFiC REPORts |  (2018) 8:9209  | DOI:10.1038/s41598-018-27265-9
target8,9. Accordingly, a number of studies have used serum and plasma to establish or identify protein markers 
for atherosclerosis10,11. These have ranged from targeted comparisons, i.e. based on prior hypothesis, through to 
untargeted profiling discovery measurements12,13. As an example of the former, Malaud et al. determined pro-
teomic profiles of atherosclerotic lesions, followed by Luminex immunoassays of likely targets in blood from 
the same subjects14. Using a discovery approach, DeGraba et al. employed surface-enhanced laser desorption/
ionization (SELDI)-time of flight (TOF) mass spectrometry to identify distinguishing proteomics patterns from 
serum samples of atherosclerotic and non-atherosclerotic groups12. Employing a multi-faceted discovery strategy, 
Kristensen et al. compared subjects with different circulatory diseases using a combination of immuno-affinity 
depletion, isobaric labeling, and an additional consideration of phosphorylated and sialyated peptides. Vinculin 
was identified as a novel marker of acute coronary syndrome13.
In contrast to the published studies, in which the comparisons have mostly addressed advanced atheroscle-
rotic phenotypes, we have analyzed serum samples taken early on from the subjects with a non-obstructive plaque 
in their carotid artery along with the matched controls. The samples were collected as part of The Cardiovascular 
Risk in Young Finns Study (YFS), which was established to investigate how childhood lifestyle, biological and 
psychological measures contribute to cardiovascular risk. Follow-up data on cardiovascular risk factors (e.g. body 
weight, blood pressure and other biochemical parameters) have been periodically determined at three to six 
years intervals from over two thousand YFS participants during the past thirty years. Ultrasound assessment of 
carotid plaque formation has also been performed during the last fifteen years15. On the basis of these ultrasound 
measurements, serum samples were selected from subjects (N = 43), in whom early signs of plaque development 
was discerned, together with the equivalent material from carefully matched controls (N = 43). With the view to 
identify markers of disease risk and onset, we have applied a label-free quantitative mass spectrometry approach 
to analyze this unique sample set16. Selected reaction monitoring mass spectrometry (SRM-MS) was subsequently 
used for the verification of the observed differences. The label-free strategy employed was advantageous in terms 
of ease of implementation and scalability. Additionally, targeted mass spectrometry-based validation assays could 
be quickly developed from the discovery data and applied to validate the results.
Results
Discovery phase of premature carotid atherosclerosis biomarkers. Label-free quantitative pro-
teomics was performed on serum samples obtained from 43 subjects who developed premature carotid artery 
plaques and 43 matched controls (Figure 1 and Table 1). Overall 296 proteins were detected with more than 1 
peptide, according to the defined filtering criteria (see Methods section). For statistical analysis, 249 proteins 
with valid values in at least 50% of the samples were further considered (Supplementary Table 1). Notably, whilst 
atherosclerosis is characterized as an inflammatory disease, our clinical data from this study of the early phases of 
plaque formation revealed that there were no differences in the level of inflammatory C-reactive protein between 
cases and controls (Table 1).
The comparison of the samples from the plaque bearing subjects and their controls revealed the differential 
abundance of seven proteins (p < 0.05) as shown in Table 2 and depicted as a volcano plot in Fig. 2. Fibulin 1 pro-
teoform C (FBLN1C), Beta-ala-his-dipeptidase (CNDP1), Cadherin-13 (CDH13), Gelsolin (GSN) and 72 kDa 
type IV collagenase (MMP2) were lower in abundance in cases, whilst apolipoprotein C-III (APOC3) and apo-
lipoprotein E (APOE) were more abundant. After correction for multiple hypothesis testing only the difference 
in the FBLN1C levels was statistically significant (FDR < 0.05). On the basis of the known genetic associations, 
we evaluated the APOE genotype data but found no difference in the frequency of the carotid atherosclerosis risk 
related alleles between the case and control groups (Supplementary Fig. S2 and Supplementary Table 2).
Machine learning classification. To gain an overview of whether there was a panel of proteins that could 
be used to distinguish the subjects we applied Lasso penalized logistic regression to the serum proteomics data. 
On the basis of this, a panel of three proteins, FBLN1C, APOE and CDH13, was observed to provide the best 
discrimination between the cases and controls. With the inclusion of APOE and CDH13, there was a statistically 
Figure 1. A Schematic representation of the study. Serum samples were selected from subjects of the YFS 
prospective study cohort on the basis of ultrasonic assessment of carotid artery intima-media thickness, with 
control samples selected on the basis of age, gender, body weight and systolic blood pressure (N = 43 vs. 43). 
Mass spectrometry-based serum proteomics analysis of depleted serum was used. The representation of human 
outline was adapted from Motifolio (www.motifolio.com).
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significant improvement in the AUROC (0.79, 95% CI: 0.69–0.88, p = 0.03) (Fig. 3). FBLN1C alone classified 
cases from controls with an AUROC value of 0.67 (95% CI: 0.56–0.79).
SRM Verification. SRM measurements were performed for the seven proteins that were indicated to be dif-
ferentially abundant in the initial profiling data. Additional targeted measurements were made for two house-
keeping proteins (selected based on their consistency in our data), APOB (an established CVD risk factor) and 
standard retention time peptides (iRT)17 (Table 3). The analysis supported the downregulation of FBLN1C by a 
ratio of 0.85 (99% CI: 0.73–0.98; FDR < 0.05) in cases compared to their matched controls (Fig. 4). There were, 
Variables
Control Case
Average SD N Average SD N
IMT 0.55 0.04 43 0.7 0.1 43
BMI, kg/m2 25.72 3.84 43 25.69 3.33 43
Systolic BP, mm Hg 124.02 11.7 43 126.45 13.58 43
Diastolic BP, mm Hg 76.29 10.14 43 79.2 12.31 43
Triglycerides, mmol/L 1.33 0.65 43 1.61 1 43
APOA1 1.65 0.24 43 1.55 0.23 43
APOB 1.04 0.25 43 1.2 0.26 43
CRP, mg/L 1.73 2.19 43 1.66 3.25 43
HDL-cholesterol, mmol/L 1.39 0.29 43 1.23 0.34 43
Table 1. Clinical parameters at the time of plaque detection. IMT, indicates intima-media thickness; BMI, 
body mass index; BP, blood pressure; APOA1, apolipoprotein A1; APOB, apolipoprotein B100; CRP, C-reactive 
protein; HDL, high-density lipoprotein; N, number of participants. Note: From the cases and controls there 
were 7 and 5 smokers, respectively (including two case-control pairs).
UniProt IDs Protein name
No. of  
unique + razor peptides
Sequence 
coverage (%)
Log 2 fold 
change p value FDR
P23142-4 Fibulin-1 proteoform C 6 36.6 −0.27 0.004 0
P02649 Apolipoprotein E 34 80.1 0.22 0.01 NS
P06396 Gelsolin 70 75.8 −0.13 0.03 NS
P02656 Apolipoprotein C-III 8 62.6 0.4 0.03 NS
P08253 72 kDa type IV collagenase 3 7.4 −0.35 0.04 NS
P55290 Cadherin-13 5 9.3 −0.32 0.04 NS
Q96KN2 Beta-Ala-His dipeptidase 29 57.6 −0.19 0.04 NS
Table 2. List of proteins found to be significantly differentially abundant between cases and their matched 
controls. FDR = 0 represents a value < 0.0001, NS = not significant.
Figure 2. A volcano plot showing the differential level of proteins between subjects who developed plaques 
and controls (N = 43 vs. 43). Each point represents a protein. The FDR corrected P-values were calculated by 
permutation (1000 times). Only the difference in FBLN1C was significant after multiple hypothesis testing, 
whilst the other labeled proteins had p < 0.05.
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however, no significant differences observed in any of the other targets. The SRM measurements for the panel did 
not improve the classification of the cases from controls as in the discovery phase (Supplementary Figure S3).
Discussion
In this comparison of serum from matched controls and subjects in whom the early stages in the development 
of carotid plaques were detected, the proteomic analysis indicated the differential abundance of several proteins. 
Figure 3. Receiver operating characteristics (ROC) curve for the determined panel of three proteins. P23142-4 
(FBLN1C) alone classified cases from controls with AUROC = 0.67 (95% CI: 0.56–0.79). The addition of 
P02649 (APOE) and P55290 (CDH13) to FBLN1C significantly improved AUROC to 0.79 (95% CI: 0.69–0.88) 
(p = 0.03). (N = 43 vs. 43).
Uniprot IDs Protein name Peptide Sequence
Peptide Sequence 
Length
P04114 Apolipoprotein B-100 EYSGTIASEANTYLNSK 17
P04114 Apolipoprotein B-100 ENFAGEATLQR 11
P04114 Apolipoprotein B-100 EVGTVLSQVYSK 12
P02656 Apolipoprotein C-III DALSSVQESQVAQQAR 16
P02656 Apolipoprotein C-III GWVTDGFSSLK 11
P04217 Alpha-1B-glycoprotein NGVAQEPVHLDSPAIK 16
P04217 Alpha-1B-glycoprotein SGLSTGWTQLSK 12
P09871 Complement C1s subcomponent IIGGSDADIK 10
P09871 Complement C1s subcomponent TNFDNDIALVR 11
P09871 Complement C1s subcomponent GDSGGAFAVQDPNDK 15
P23142-4 Fibulin-1 proteoform C DLLLTVK 7
P23142-4 Fibulin-1 proteoform C HGTVSSFVAK 10
P02649 Apolipoprotein E LGPLVEQGR 9
P02649 Apolipoprotein E LEEQAQQIR 9
P06396 Gelsolin AGALNSNDAFVLK 13
P06396 Gelsolin TPSAAYLWVGTGASEAEK 18
P08253 72 kDa type IV collagenase IIGYTPDLDPETVDDAFAR 19
P08253 73 kDa type IV collagenase AFQVWSDVTPLR 12
P55290 Cadherin-13 DVGKVVDSDRPER 13
P55290 Cadherin-13 INENTGSVSVTR 12
Q96KN2 Beta-Ala-His dipeptidase EWVAIESDSVQPVPR 15
Q96KN2 Beta-Ala-His dipeptidase FRQELFR 7
Q96KN2 Beta-Ala-His dipeptidase ALEQDLPVNIK 11
Table 3. List of proteins along with their proteotypic peptides used for the SRM-MS assay.
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Amongst these were a number of proteins that have been previously linked with atherosclerosis, i.e. APOC3, 
APOE, CNDP1, CDH13, GSN, MMP2 and fibulin18. Using a machine learning approach the combination of 
FBLN1C, APOE and CDH13 was found to provide the best classification of the cases from controls. A targeted 
SRM assay was subsequently developed for the measurement of these differentially abundant proteins. Due to 
the unavailability of a similar sample set, it was used for verification only in the same samples as analyzed in the 
discovery phase. The verification measurements were performed for the samples prepared without depletion. 
The use of undepleted samples removed potential biases created by the depletion step and succeeded against the 
background of abundant serum proteins due to the intrinsic sensitivity of the targeted method. Based on this 
verification data, the quantitative difference of FBLN1C remained significant. The failure to confirm the dissimi-
larities detected for APOE and CDH13 in the discovery data could reflect the small magnitude and variability of 
these intra-individual differences.
The Fibulins are a family of six moderately abundant serum proteins (FBLN1 – FBLN6) that are linked with 
the extracellular matrix (ECM) proteins18. Differences in FBLN1 abundance have previously been observed in 
several studies, including its relationship to atherosclerosis, cardiovascular risk, arterial stiffness and type 2 dia-
betes (T2D). For example, Kawata et al. first reported reduced plasma levels of FLBN1 in patients with acute 
myocardial infarction and stable angina19. Both lower and higher levels have been reported in the plasma of T2D 
patients20,21, but differences in the duration of the disease (recently diagnosed vs. established disease) could reflect 
upon the latter division. In relationship to cardiovascular disease, FLBN1 was detected as a component of ather-
osclerotic lesions, and Argraves et al. suggested that decreased plasma FBLN1 could reflect its accumulation in 
the plaque22. Similarly, the accumulation of FBLN1 in the arterial wall has been detected in patients with T2D21, 
although in a situation in which the FBLN1 plasma levels were higher than in the matched controls. In contrast, 
in newly diagnosed T2D patients, lower plasma FBLN1 was found and correlated with carotid-femoral arterial 
stiffness20. On the basis of the latter observation, Paapstel et al. studied the relationship between arterial stiffness 
and serum FBLN1 levels in patients with atherosclerosis23. Here they found higher levels of FBLN1 in the patients.
In addition to the complex interplay between arterial stiffness and atherosclerotic risk factors24, the relation-
ship between plasma levels of FBLN1 and the early stages of plaque formation is contradictory and yet to be 
clearly established.
In the above examples, there are differences in the study sizes, diseases and duration, as well as specificity 
of the controls. Further, whilst alternative splicing produces four FBLN1 proteoforms (A, B, C and D)25, the 
former the studies have not made any distinction between these. These variants may differ from both a struc-
tural and functional perspective. In this respect their distinction as proteoforms and this terminology impli-
cates protein variants that are not coded explicitly in the genome, i.e. including alternative RNA splicing and 
post-translational modifications26. Our proteomic data has specifically highlighted significant differences for the 
C proteoform. Fibulin1C has been reported to be the predominant form in plasma25 and has been identified in 
the tissue secretome analysis of coronary arteries27. Within the limitations of this knowledge, we can only spec-
ulate whether this difference in abundance represents a phenotype that is more susceptible to plaque formation 
or an early indication of onset. Potentially, it may be that the structural differences for this specific proteoform 
of FBLN1 could, following some trigger, contribute to its interaction with extracellular matrix protein (ECM) 
molecules and accumulation on the arterial intimal walls, and thus be reflected by its lower serum abundance.
The progression of the atherosclerotic process is influenced by a range of factors including age, diet, stress and 
other risk factors such as smoking28,29. In the present study the subjects were carefully matched by age, gender, 
BMI and blood pressure. However, seven cases and five controls were smokers, and the influence of smoking was 
not separately evaluated. Additional limitations of the current study is the sample size and the need for further 
Figure 4. Box-Whisker plot showing relative abundance of FBLN1C measured using SRM-MS assay in the YFS 
cohort (control, N = 43; cases, N = 43). The relative abundance of FBLN1C was found to be lower in cases than 
controls (Adjusted p-value = 0.039). Mass spectrometry-based serum proteomics analysis of undepleted serum 
was used.
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validation studies in a larger independent cohort. Furthermore, structural studies explaining the interaction of 
the FBLN1C proteoform with ECM proteins could provide insights into its potential role in plaque formation.
In summary, from these measurements from a cohort selected to study the risk and development of ather-
osclerotic lesions, distinguishing proteomics profiles were identified in subjects showing early signs of plaque 
development. In particular, FBLN1C is implicated as a target for further investigation
Methods
Study Population and design. The samples were selected from participants in the Cardiovascular Risk 
in Young Finns cohort15. On the basis of carotid ultrasound measurements, samples from 43 individuals with a 
distinct carotid artery plaque were selected together with samples from 43 controls. The controls were matched by 
age, sex, body weight and systolic blood pressure. The age range of the subjects was 30–45 years. The study design 
is depicted in Fig. 1, and the clinical characteristics of cases and controls are shown in Table 1. The measurements 
and data included in this manuscript have been acquired following the guidelines of the Declaration of Helsinki 
for research on human participants and were conducted with the permission of the Ethical Committees of the 
University Hospitals of Turku with written informed consent.
Carotid intima-media thickness measurement. Ultrasound examination of the left carotid artery, 
including common carotid artery and carotid bifurcation, were performed using B-mode ultrasound (Acuson 
Sequoia 512, Siemens) with the 13.0-MHz linear-array transducer, according to a standardized protocol30. 
Intima-media thickness was measured from digitally stored scans by one reader blinded to participant details. The 
best-quality end-diastolic frame was selected, and ultrasonic calipers were used to measure carotid intima-media 
thickness from the far wall of the common carotid artery 10 mm proximal to the bifurcation. To detect the 
carotid plaques, the images were scanned and the presence of atherosclerotic plaque defined as a distinct area of 
the carotid vessel wall protruding into the lumen >50% of the adjacent intima-media layer31. All the observed 
plaques were detected in the carotid bifurcation.
ApoE genotype determination. APOE genotyping was performed by using TaqMan SNP Genotyping 
Assays (rs429358 assay C 3084793_20; rs7412 assay C_904973_10) and the ABI Prism 7900HT Sequence 
Detection System (Applied Biosystems, Foster City, CA, USA).
Sample preparation. Immunodepletion of high abundant proteins. An Agilent MARS-14 immunoaffinity 
column was used for the targeted removal of the most abundant serum proteins. The isolated, lower abundance 
proteins were reduced, alkylated, digested and desalted prior to mass spectrometry (MS) analysis as described 
previously32.
Preparation of undepleted serum. For the verification measurements, the serum samples were diluted in the 
denaturant, reduced, alkylated and digested using sequencing grade modified trypsin (Promega)32.
Heavy labeled synthetic analogs of proteotypic peptides33 of the differentially abundant proteins, housekeep-
ing proteins (Alpha-1B-glycoprotein and complement C1s subcomponent) and the known CVD risk factor, 
Apolipoprotein B-100, were spiked into the digests together with indexed retention time standard (iRT) peptides 
(Biognosys). These were selected from discovery phase peptide data with the consideration of the consistent 
detection, absence of potentially modified residues and missed cleavages (Table 3). The heavy-labeled synthetic 
analogs (lysine 13C6 15N2 and arginine 13C6 15N4) equivalent of proteotypic peptides were obtained (Thermo 
Fischer Scientific).
Mass spectrometry analysis. Discovery phase. Aliquots of the depleted serum digests (500 ng) were ana-
lyzed with an Easy-nLC-II coupled to a LTQ Orbitrap Velos Pro mass spectrometer (Thermo Fisher Scientific). 
The peptides were separated on 150 mm × 75 µm ID column packed with 5 µm magic C18-bonded silica 
(200 Å). The peptides were eluted with an increasing gradient of 5–35% acetonitrile at a flow rate of 300 nl/min 
using a binary mixture of water and acetonitrile with 0.2% formic acid. The mass spectrometer was operated in 
data-dependent acquisition mode with a selection of top 15 precursors followed by fragmentation using col-
lisional induced dissociation (CID) method. All the samples were analyzed in quadruplicate as randomized 
batches32. To ensure comparable instrument performance throughout the time span of the discovery phase study, 
an in-house standard was periodically analyzed to establish the consistency of the signal intensity and chromato-
graphic separation (Supplementary Figure S1).
Verification. Aliquots of the digested peptides (250 ng), spiked with heavy labeled peptides and index reten-
tion time (iRT) peptides, were analyzed with Easy-nLC-II coupled to a TSQ Vantage mass spectrometer 
(Thermo Fisher Scientific)32. The peptide mixture was separated with a 150 mm × 75 µm ID column packed with 
ReproSil-Pur C18-AQ 5 µm resin (Dr. Maisch GmbH). An unscheduled analysis of the sample was carried out 
to generate iRT values of target peptides and their heavy counterparts. Skyline software was used to build up the 
scheduled method for the selected targets using the unscheduled run. The scheduled method was then edited by 
removing interfering signals32 to monitor 99 transitions from 33 peptides, representing 10 proteins and the iRT 
peptides.
The 86 serum samples (N = 43 vs. 43) were prepared without depletion and analyzed as randomized batches. 
To monitor the variation of peak areas and retention time across and within the batches, a pooled digest of the 
undepleted serum was included in each batch.
Data processing. Protein informatics analysis (Discovery phase). The tandem mass spectra data were searched 
against a UniProt human isoform protein sequence database (UniProt release, August 2017, entries = 42,210) 
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using the Andromeda34 search algorithm and MaxQuant 1.5.5.135. The search parameters were set to allow two 
missed tryptic cleavages, methyl methanethiosulfonate (MMTS) modification of cysteine and variable modifi-
cation of methionine and acetylation of the protein N terminus. A false discovery rate (FDR) of 1% was applied 
at peptide and protein level. The “match between run” option (matching and alignment time window = 0.7 and 
20 minutes respectively) was selected in order to enable the transfer of identifications across the mass spectromet-
ric measurements36. The label-free normalized intensity values (MaxQuant output) were further analyzed using 
Perseus software36,37. Briefly, the output was filtered to exclude reverse hits and proteins only inferred by the detec-
tion of single variable modifications. Furthermore, only proteins identified with >1 unique plus razor peptides 
were considered. The razor peptides are defined as those that are shared between different protein groups and are 
assigned to the protein that has the most peptides35,38. The data was then log2 transformed followed by filtering 
to at least 50% valid values. Missing values were imputed by “imputation from normal distribution” (width = 0.3, 
downshift = 1.8)39 followed by taking the average of quadruplicate analyses. The subsequent statistical analysis of 
data was then performed using R40.
SRM data analysis and transition selection. Skyline version 4.1 was used to develop and analyze SRM assay 
transitions41. The quality of the transitions and confirmation of light/heavy pairs were manually inspected. On 
account of interferences in the transitions for one of the FBLN1C peptides, DLLLTVK alone was considered for 
its statistical analysis in the SRM data. Out of the two housekeeping proteins included for normalization of the 
data, the TNFDNDIALVR peptide from complement C1s subcomponent was used.
Statistical analysis. Reproducibility-optimized test statistic (ROTS). The label-free normalized protein 
intensity abundance values obtained from MaxQuant analysis were used as input for ROTS analysis36,42,43. Briefly, 
the log2 transformed data were analyzed using non-parametric method relying on the family of t-type statistics 
which ranks the proteins based on their differential expression in two group conditions and the calculation was 
made with 1000 permutations (FDR < 0.05).
Machine learning classification. To identify the protein panel with the highest discriminative performance, Lasso 
penalized logistic regression44, implemented in the R package glmnet45, was applied to the serum proteomics data. 
First, all candidate predictors were identified by shrinking the coefficients of non-informative predictors to zero 
using Lasso with 3-fold cross-validation, repeating the randomization procedure 200 times. In each fold, only 
significantly differentially abundant proteins (ROTS; P < 0.05) were considered. Finally, among the top 20 most 
frequent candidate proteins, the Lasso model with the protein panel having the largest improvement in discrim-
inative performance in terms of area under the receiver-operating characteristic curve (AUROC) and with the 
least number of predictors was identified. Statistical significance of the differences in the AUROC values between 
the models was determined using the DeLong method46 implemented in the R package pROC47.
MSStats. The MSStats (3.8.4) plugin included in the Skyline software was used for the group comparison 
between cases and controls48. Briefly, after normalizing the data to the housekeeping protein the statistics were 
calculated on the basis of the Turkey’s median polish method. The latter uses a linear mixed model to give a robust 
estimation of differentially abundant proteins between conditions.
Data availability. The LC-MS/MS proteomics discovery data are available from the ProteomeXchange 
Consortium via the PRIDE49 partner repository with the dataset identifier PXD008278. The SRM verification 
data are available from the ProteomeXchange Consortium via the PASSEL50 partner repository with dataset iden-
tifier PASS01146.
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